Can we use mineralocorticoid receptor blockade in diabetic patients with resistant hypertension? Yes we can! But it may be a double-edged sword
J Hypertens
.
2013 Oct;31(10):1948-51.
doi: 10.1097/HJH.0b013e328364bcdf.
Authors
Michel Azizi
1
,
Matthieu Monge
,
Aurélien Lorthioir
,
Guillaume Bobrie
,
Laurence Amar
Affiliation
1
aAssistance Publique - Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Hypertension Unit bUniversité Paris-Descartes cINSERM, Clinical Investigation Centre 9201, Paris, France.
PMID:
24107727
DOI:
10.1097/HJH.0b013e328364bcdf
No abstract available
Publication types
Editorial
Comment
MeSH terms
Blood Pressure / drug effects*
Diabetes Complications / drug therapy*
Female
Humans
Hypertension / drug therapy*
Male
Spironolactone / administration & dosage*
Spironolactone / therapeutic use*
Substances
Spironolactone